Amgen Inc. $AMGN Shares Sold by Mackenzie Financial Corp

Key Points

• Mackenzie Financial trimmed its stake in Amgen by 4.2% in Q3, selling 7,056 shares and leaving 161,778 shares valued at $45.65 million; institutional investors now own about 76.5% of the stock.
• Amgen beat Q4 estimates with $5.29 EPS versus $4.76 expected and $9.87 billion in revenue (up 8.6% year‑over‑year) and issued FY2026 guidance of 21.60–23.00 EPS.
• The company declared a quarterly dividend of $2.52 per share (annualized $10.08, ~2.7% yield, ex‑dividend May 15), while analysts show a consensus rating of Hold with an average price target of $354.00.

Mackenzie Financial Corp trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 161,778 shares of the medical research company's stock after selling 7,056 shares during the period. Mackenzie Financial Corp's holdings in Amgen were worth $45,654,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Evelyn Partners Investment Management LLP purchased a new stake in Amgen in the 2nd quarter valued at $32,000. Howard Hughes Medical Institute purchased a new position in shares of Amgen during the second quarter worth about $32,000. Cloud Capital Management LLC acquired a new position in Amgen in the 3rd quarter valued at about $34,000. AXS Investments LLC acquired a new stake in Amgen during the 3rd quarter worth approximately $42,000. Finally, Winnow Wealth LLC purchased a new position in shares of Amgen in the 3rd quarter valued at approximately $47,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: MariTide and osteoporosis drug sales cited as a key driver of recent investor enthusiasm; analysts/coverage note product momentum that helped push earlier gains. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Operational/production support: Rapid Micro Biosystems reported that Amgen expanded a global Growth Direct system rollout (multi‑system order), signaling investments in manufacturing capacity and process efficiency. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Positive Sentiment: Institutional buying/positioning: Amgen is highlighted as a holding in a large income fund, reflecting demand from dividend/income managers seeking defensive, high‑yield large caps. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Macro/sector support: Prominent market commentators have endorsed large‑cap biotech as resilient growth plays, which supports longer‑term investor interest. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Company presentation: A recent Leerink Global Healthcare conference transcript provides updated management commentary — useful for gauging near‑term guidance and pipeline cadence but not an immediate catalyst by itself. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Valuation discussion: Coverage pieces assessing whether AMGN is mispriced highlight mixed returns vs. peers — useful context for investors but not a direct price mover. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest data appears to contain errors (reports show zero shares/NaN changes and a 0.0 days-to-cover figure); there’s no clear evidence of meaningful short pressure at present.
• Negative Sentiment: Analyst stance: Jefferies initiated coverage with a Hold recommendation, which can cap momentum relative to a Buy/Outperform narrative and may contribute to near‑term selling pressure. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Truist Financial increased their price target on Amgen from $318.00 to $319.00 and gave the stock a "hold" rating in a report on Thursday, January 8th. Sanford C. Bernstein downgraded shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price objective for the company. in a research report on Tuesday, January 20th. Guggenheim increased their target price on Amgen from $305.00 to $347.00 and gave the stock a "neutral" rating in a research note on Friday, February 6th. UBS Group upped their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Finally, Jefferies Financial Group started coverage on Amgen in a research report on Tuesday. They set a "hold" rating and a $350.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $354.00.

Amgen Price Performance

AMGN opened at $367.79 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The firm has a market cap of $198.26 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 3.75 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company has a fifty day simple moving average of $356.96 and a 200 day simple moving average of $324.63.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period last year, the firm earned $5.31 earnings per share. The company's revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen's payout ratio is 70.84%.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.